Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Net Margin (2016 - 2025)

Historic Net Margin for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to 3.04%.

  • Anika Therapeutics' Net Margin rose 980100.0% to 3.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.64%, marking a year-over-year decrease of 27600.0%. This contributed to the annual value of 39.66% for FY2024, which is 259300.0% up from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Net Margin is 3.04%, which was up 980100.0% from 2.4% recorded in Q2 2025.
  • Anika Therapeutics' 5-year Net Margin high stood at 17.12% for Q2 2021, and its period low was 558.26% during Q4 2023.
  • Its 5-year average for Net Margin is 59.66%, with a median of 7.93% in 2022.
  • Its Net Margin has fluctuated over the past 5 years, first tumbled by -3522900bps in 2022, then soared by 4949400bps in 2024.
  • Over the past 5 years, Anika Therapeutics' Net Margin (Quarter) stood at 9.03% in 2021, then crashed by -3902bps to 361.32% in 2022, then crashed by -55bps to 558.26% in 2023, then skyrocketed by 89bps to 63.33% in 2024, then soared by 105bps to 3.04% in 2025.
  • Its Net Margin stands at 3.04% for Q3 2025, versus 2.4% for Q2 2025 and 3.5% for Q1 2025.